title: Short-term oral pentoxifylline use increases choroidal blood flow in patients with age-related macular degeneration.
abstract: OBJECTIVE
  To study the ocular hemodynamic effects of a 3-month oral treatment with pentoxifylline in patients with nonexudative age-related macular degeneration.
  
  
  METHODS
  Double-blind, placebo-controlled, randomized, parallel group study.
  
  
  METHODS
  Outpatient clinic of the Department of Ophthalmology, Vienna University, Vienna, Austria, that specializes in age-related macular degeneration.
  
  
  METHODS
  Forty patients with age-related macular degeneration received pentoxifylline (400 mg 3 times a day orally, n=20) or placebo (n=20) for 3 months. Retinal blood flow was assessed by scanning laser Doppler flowmetry and pulsatile choroidal blood flow was assessed by laser interferometric measurement of fundus pulsation amplitude.
  
  
  METHODS
  Changes in retinal blood flow and fundus pulsation amplitude.
  
  
  RESULTS
  Four patients receiving pentoxifylline and 3 patients receiving placebo discontinued medication because of nausea. In the remaining subjects, the use of pentoxifylline increased ocular fundus pulsation amplitude (P<.001 vs placebo and baseline). The maximum increase was 28% after 3 months. In contrast, retinal blood flow was not changed by the use of pentoxifylline.
  
  
  CONCLUSIONS
  A 3-month course of oral pentoxifylline treatment increases choroidal but not retinal blood flow in patients with age-related macular degeneration. These data strongly support the concept that pentoxifylline might be useful in the treatment of age-related macular degeneration. Long-term clinical outcome trials are now warranted to test this hypothesis.
authors.affiliation: Department of Clinical Pharmacology, Vienna University, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Kruger
authors.forename: B
authors.initials: B
authors.lastname: Matulla
authors.forename: M
authors.initials: M
authors.lastname: Wolzt
authors.forename: S
authors.initials: S
authors.lastname: Pieh
authors.forename: K
authors.initials: K
authors.lastname: Strenn
authors.forename: O
authors.initials: O
authors.lastname: Findl
authors.forename: H G
authors.initials: HG
authors.lastname: Eichler
authors.forename: L
authors.initials: L
authors.lastname: Schmetterer
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D001783:Blood Flow Velocity / Q000187:drug effects; D002829:Choroid / Q000098:blood supply* / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017078:Laser-Doppler Flowmetry; D008268:Macular Degeneration / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D012171:Retinal Vessels / Q000503:physiopathology; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D014665:Vasodilator Agents; D010431:Pentoxifylline